Ala(2)- glucose-dependent insulinotropic polypeptide

Also Known As:

glucose-dependent insulinotropic polypeptide, Ala(2)-; (d-Ala2)GIP; 2-Ala-glucose-dependent insulinotropic polypeptide; glucose-dependent insulinotropic polypeptide, alanyl(2)-

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Flatt, Peter R: 1 article (01/2020)
2.	Gault, Victor A: 1 article (01/2020)
3.	Gribble, Fiona M: 1 article (01/2020)
4.	Irwin, Nigel: 1 article (01/2020)
5.	Moffett, R Charlotte: 1 article (01/2020)
6.	Reimann, Frank: 1 article (01/2020)
7.	Sarnobat, Dipak: 1 article (01/2020)
8.	Tanday, Neil: 1 article (01/2020)

Related Diseases

1.	Body Weight (Weight, Body) 01/01/2020 - "Twice-daily administration of (D-Ala2)GIP, xenin-25[Lys13PAL] or (D-Ser2)-Oxm[Lys38PAL] for 10 days to streptozotocin (STZ)-induced diabetic mice did not affect body weight, food intake or blood glucose levels, but (D-Ser2)-Oxm[Lys38PAL] reduced (P < 0.05 to P < 0.001) fluid intake and circulating glucagon. "

Related Drugs and Biologics

1.	Streptozocin (Streptozotocin)
2.	Glucagon (Glukagon)
3.	Blood Glucose (Blood Sugar)
4.	xenin 25 (xenin)